« Back
Home /
Naproxen Sodium

Naproxen Sodium

Item no.	S1626-200
Manufacturer	Selleckchem
CASRN	26159-34-2
Amount	200 mg
Quantity options	10 mM/1 ml 200 mg 50 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer
Type	Inhibitors
Specific against	other
Smiles	CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].[Na+]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	RS-3650
Similar products	Naproxen
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	252, 24
Administration	Intravenously (i.v.) infusion or intraperitoneal (i.p.) injection
Animal Models	Male Sprague-Dawley rats
Cell lines	Human colon cancer HCA-7 cell lines
Clinical Trials	Phase IV completed in testing the effect on blood pressure of sumatriptan and Naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only Naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
Concentrations	Dissolved in culture medium, final concentration ca.20 mM
Dosages	2.5, 10 or 25 mg/kg
Formulation	Dissolved in 0.9% NaCl
IC50	2.2 ug/mL, 2.2 ug/mL, 2.2 ug/mL, 2.2 ug/mL, 2.2 ug/mL, 2.2 ug/mL
In vitro	Naproxen is approximately equipotent inhibitor of COX-1 and COX-2 in intact cells with IC50 of 2.2 ug/mL and 1.3 ug/mL, respectively. [1] Naproxen decreases the in vitro LPS-induced PGE2 and TXB2 production in rats and humans with IC50 of 30.7 uM and 79.5 uM for PGE2 inhibition, 72.4 uM and 48.3 uM for TXB2 inhibition, respectively. [2] Naproxen produces concentration-related inhibition of TXB2 production from human platelets and LPS-induced TXB2 production from human mononuclear cells with plC50 values (-log concentration inhibiting TXB2 by 50%) of 5.7 and 6.4, respectively, and exhibits slightly inhibitory selectivity for constitutive and induced COX-2 with IC50 COX-1/IC50 COX-2 of 6.3. [3] Only high concentration of Naproxen can significantly induce apoptosis at 48 hours in HCA-7 colon cancer cells with IC50 of 1.45 mM. [4]
In vivo	Administration of Naproxen reduces the LPS-induced PGE2 and TXB2 production in vivo in rats with IC50 values of 12.8 uM and 5.9 uM, respectively, which represents that Naproxen is a nonselective COX inhibitor with the log IC50 ratio (COX-2/COX-1) of 0.34. [2] Naproxen displays IC50 of 27 uM for analgesia in a rat model with carrageenan-induced arthritis and IC50 of 40 uM for antipyretics in a yeast-induced fever rat model, while exhibits inhibition of PGE2 with IC50 of 13 uM and TXB2 with IC50 of 5 uM. [5]
Incubation Time	24 and 48 hours
Kinase Assay	COX-1 and COX-2 activities in intact cells, For the determination of COX-1 and COX-2 inhibition, bovine aortic endothelial cells (BAEC) are incubated for 30 minutes with Naproxen (0.1 ng/mL to 1 mg/mL), and cultured J774.2 macrophages are treated with endotoxin at 1 ug/mL for 12 hours to induce COX-2 followed by incubated for 30 minutes with Naproxen (0.1 ng/mL to 1 mg/mL), respectively. Arachidonic acid (30 uM) is then added, and the cells are incubated for a further 15 minutes at 37 C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF1alpha, PGE2, thromboxane B2, or PGF2alpha for the assessment of IC50 for COX-1 and COX-2.
Method	Cells are exposed to Naproxen for 24 and 48 hours, respectively. At the end of incubation, cells are harvested by trypsinization, stained with trypan blue solution (0.04% wt/vol) and counted in a Neubauer haemocytometer chamber for the determination of cell viability.
Solubility (25C)	DMSO 3 mg/mL, Water 76 mg/mL, Ethanol 15 mg/mL
Information	Naproxen Sodium (RS-3650) is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively.
Chemical Name	sodium (S)-2-(6-methoxynaphthalen-2-yl)propanoate
Features	Naproxen displays approximately equipotent inhibitory selectivity for COX-1 and COX-2 in intact cells.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S1626-200-datasheet.pdf

S1626-200-safety-datasheet.pdf